The Future of Science is Here

Biostatistics
Strategic Partners in Drug Development

At Genentech, Biostatistics is a strategic partner in drug development. We take leadership roles in many aspects of drug development, including the design, analysis and interpretation of clinical trials. We apply our statistical expertise and critical thinking to translate biologic concepts to measurable hypotheses and into vital drug development evidence.

Through our collaborations, we promote rigor in the planning and conduct of studies, and in the interpretation of results from diverse data sources and analytical approaches. We advocate the principles of statistics to facilitate rigorous evidence generation and decision-making throughout the company.

Our contributions span from research applications through the lifecycle of our medicines, from nonclinical studies to first in human clinical trials, through regulatory approval and market access, as well as manufacturing.
WHO WE ARE

For more than 40 years, Genentech has been at the forefront of the biotechnology industry, using innovative science to discover, develop, manufacture and commercialize breakthrough medicines that improve the lives of people with serious or life-threatening diseases.

A member of the Roche Group since 2009, we are considered one of the founders of the biotech industry and continue to be an industry leader, with multiple drugs on the market and several more promising drugs in our pipeline.

How do we do it? We come to work every day with a sense of urgency, uncompromising ethics and passion for transforming lives. What’s best for the patient drives our decisions, and our commitment to scientific rigor is second to none.

It’s all so we can do now what patients need next.

CELEBRATING DIVERSITY AND INCLUSION

At Genentech, we believe diversity plays a critical role in our ability to discover life-saving drugs. We celebrate different approaches and new ideas—we welcome them. Those new and different ideas not only help create a vibrant, exciting place to work, but also push us to innovate, to make breakthroughs.

We are committed to continuing to increase our diversity. And we have several programs in place to help:

• Gender Diversity Strategy: We have implemented several strategies to help us bring more women into leadership positions at Genentech.

• DNA Groups (Diversity Network Associations): Today, more than 5,300 employees belong to one of our internal DNA Groups, which offer a chance for employees with similar interests or experiences to connect.

• Veteran Recruitment: We recognize and celebrate the contributions of our veterans and are working to build messaging pathways that let veterans know about the opportunities available at Genentech.

• Disability Inclusion: We are committed to ensuring accessibility and employee awareness for people of all abilities.

WE INTRODUCED THE FIRST:

• Biotech company and IPO

• Recombinant biotech medicine manufactured and marketed by a biotech company

• Therapeutic antibody approved for cancer in the United States

• Personalized medicine

• Anti-angiogenesis treatment for people with cancer

• Biologic for asthma

• Biologic for cystic fibrosis

• Treatment to improve vision in up to 40 percent of patients with wet AMD

• FDA-approved medicine for people with advanced forms of the most common skin cancer

• Medicine approved with the FDA’s Breakthrough Therapy designation

• FDA-approved medicine for both relapsing and progressive forms of multiple sclerosis

• FDA-approved medicine for Erdheim-Chester Disease

• FDA-approved medicine in nearly 20 years for hemophilia A with inhibitors

Genentech has been on Fortune’s “100 Best Companies to Work For” 20 consecutive years.

WHO WE’RE LOOKING FOR

Where do you come in? If you’re passionate about your work, motivated to help others, and strategic and flexible in your thinking, we need to hear from you.

To look at opportunities within Biostatistics at Genentech, visit www.gene.com/careers.

Genentech is an Equal Opportunity Employer.